Skip to main content

Table 3 Sample’s characteristics according to the presence of no DM, prediabetes and DM, accessed by OGTT

From: Diabetes mellitus in HIV-infected patients: fasting glucose, A1c, or oral glucose tolerance test – which method to choose for the diagnosis?

  Glucose at 120 min P value
<140 mg/dL 140–200 mg/dL ≥200 mg/dL
n (%) 154 (70) 53 (24.1) 13 (5.9)  
Sex [n (%)]     0.061
 Male 101 (65.6) 26 (49.1) 6 (46.2)  
 Female 53 (34.4) 27 (50.9) 7 (53.8)  
Age [years, mean (SD)] 43.4 (10.2) 50.4 (12.1) 55 (13.6) < 0.001
Duration of HIV infection [years, median (IR)] 8 (6) 7 (6) 10 (8) 0.980
cART [years, [median (IR)] 6 (5.3) 6 (7) 9 (9) 0.566
Clinical lipodystrophy [n (%)]     0.148
 Without CL 78 (50.6) 24 (45.3) 3 (23.1)  
 With CL 76 (49.4) 29 (54.7) 10 (76.9)  
Body Composition [n (%)]     0.078
 No lipodystrophy 23 (15.5) 7 (13.5) 1 (7.7)  
 Isolated central fat accumulation 50 (33.8) 17 (32.7) 2 (15.4)  
 Lipoatrophy 45 (30.4) 11 (21.2) 2 (15.4)  
 Mixed form of lipodystrophy 30 (20.3) 17 (32.7) 8 (61.5)  
BMI [(kg/m2), [median (IR)] 24.5 (5.8) 25.4 (6.4) 25.5 (3.3)  
Waist circumference [cm, median (IR)] 90.5 (16) 91 (17.8) 95 (8.5) 0.687
CD4 cell count [cells/mm3, [median (IR)] 512.5 (336) 500 (311) 456 (509) 0.569
HIV RNA (<50) [n (%)] 138 (100) 44 (100) 10 (100)  
Hepatitis C co-infection [n (%)] 47 (30.9) 15 (28.8) 2 (16.7) 0.655
CDC clinical categories [n (%)]     0.252
 A 90 (58.4) 24 (45.3) 5 (38.5)  
 B 4 (2.6) 1 (1.9) 0 (0)  
 C 60 (39) 28 (52.8) 8 (61.5)  
ART [n (%)]     
 IP 77 (50) 36 (67.9) 10 (76.9) 0.023
 NNRTI 82 (53.2) 17 (32.1) 3 (23.1) 0.005
 NRTI 148 (96.1) 51 (96.2) 11 (84.6) 0.188
HOMA-IR index [median (IR)] 1.4 (1.5) 2.4 (2.5) 1.9 (3.2) < 0.001
QUICKI index [median (IR)] 0.4 (0.1) 0.3 (0.1) 0.4 (0.1) < 0.001
Total cholesterol [mg/dL, median (IR)] 224 (67) 224 (79) 234 (86) 0.743
LDL- cholesterol [mg/dL, median (IR)] 130 (70) 135 (66) 156 (79) 0.843
HDL- cholesterol [mg/dL, median (IR)] 49 (19) 44 (20) 52 (15) 0.314
Triglycerides [mg/dL, median (IR)] 186 (176.5) 223 (258.5) 170 (101) 0.131
Statin use [n (%)] 31 (20.1) 9 (17) 6 (46.2) 0.072
Fibrate use [n (%)] 43 (27.9) 21 (39.6) 1 (7.7) 0.061
  1. DM diabetes mellitus, OGTT oral glucose tolerance test, CL clinical lipodystrophy, cART combination antiretroviral therapy, BMI body mass index, ART antiretroviral therapy, PI protease inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, NRTI nucleoside reverse transcriptase inhibitor, HOMA homeostatic model assessment index, QUICKI quantitative insulin sensitivity check index, SD standard deviation, IR interquartile range